Hydroxychloroquine

Proactive news headlines including Radiopharm Theranostics, AuTECO Minerals, Lake Resources and Incannex Healthcare

Retrieved on: 
Tuesday, October 18, 2022

Click here

Key Points: 
  • Click here
    Regener8 Resources NL has embarked on its first-ever field campaign at the Kookynie Gold Project near Leonora in WA.
  • Click here
    Golden Rim Resources Ltd (ASX:GMR) has identified additional gold targets from a geophysical survey program at the Kada Gold Project in Guinea, West Africa.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Incannex Completes Dosing in Phase 1 Clinical Trial to Assess Multi-Use, Anti-Inflammatory Drug IHL-675A; Proceeds to Phase 2 Clinical Trials

Retrieved on: 
Thursday, October 13, 2022

MELBOURNE, Australia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed dosing of trial participants in the phase 1 clinical trial undertaken to assess pharmacokinetics and safety of the anti-inflammatory drug IHL-675A.

Key Points: 
  • The Phase 1 trial measured the safety, tolerability, and pharmacokinetic profiles of IHL-675A compared to the reference listed drugs, Epidiolex (CBD) and Plaquenil (HCQ).
  • Three cohorts of 12 participants (n = 36) received either IHL-675A, CBD or HCQ and the clinical assessments were identical across the three arms of the trial.
  • The trial was conducted by CMAX Clinical Research in Adelaide, South Australia and managed by Avance Clinical.
  • Initial reports of drug tolerability afford Incannex the opportunity to proceed with the next stage of development for IHL-675A.

BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine

Retrieved on: 
Monday, September 12, 2022

KANSAS CITY, Mo., Sept. 12, 2022 /PRNewswire/ -- BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ).

Key Points: 
  • KANSAS CITY, Mo., Sept. 12, 2022 /PRNewswire/ -- BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ).
  • Ulixertinib is a first-in-class and best-in-class ERK inhibitor, with this clinical trial focusing on patients with advanced gastrointestinal malignancies and mutations in the MAPK pathway.
  • Previous efforts have also established a recommended phase 2 dose in combination with palbociclib, with additional combination efforts ongoing.
  • About BioMed Valley Discoveries (BVD): BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs in a variety of therapeutic and diagnostic areas.

Dr. Simone Gold Press Conference Friday, September 9, 2022

Retrieved on: 
Friday, September 9, 2022

MIAMI, Sept. 8, 2022 /PRNewswire/ -- Dr. Simone Gold, founder of America's Frontline Doctors (AFLDS), will be holding a press conference tomorrow, Friday, September 9, 2022 at the Miami Federal Detention Center at 11:00AM ET, located at 33 NE 4th St, Miami, FL 33132.

Key Points: 
  • Gold was sentenced to 60 days in prison for reading prepared remarks in the US Capitol on January 6, 2021.
  • Dr. Gold, a prominent doctor and lawyer, was charged and served a federal prison term for a non-violent misdemeanor trespassing charge with no prior record.
  • During that historic press conference, viewed by over 24 million Americans, they discussed hydroxychloroquine, which has a 200% weighted average against hospitalization and death.
  • Dr. Gold intends to take questions and share new objectives regarding the AFLDS mission over the next several months.

Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)

Retrieved on: 
Tuesday, July 19, 2022

Veklury (remdesivir) is a nucleotide analog invented by Gilead, building on more than a decade of the companys antiviral research.

Key Points: 
  • Veklury (remdesivir) is a nucleotide analog invented by Gilead, building on more than a decade of the companys antiviral research.
  • As new SARS-CoV-2 variants of concern emerge around the world, Gilead continuously evaluates the effectiveness of Veklury against viral variants.
  • Veklury, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Global Oral Solid Dosage Contract Manufacturing Market to 2027 - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, July 15, 2022

Oral solids are the most widely accepted dosage forms in the pharmaceutical sector as they are cost-effective, simple to manufacture, and patient-friendly.

Key Points: 
  • Oral solids are the most widely accepted dosage forms in the pharmaceutical sector as they are cost-effective, simple to manufacture, and patient-friendly.
  • Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing drive the market growth.
  • The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and a high level of adaptability.
  • Chapter 3 Oral Solid Dosage Contract Manufacturing Market: Variables, Trends, & Scope
    3.2.2.2 Less availability of experienced technical staff, as well as physical capability and capacity of the equipment.

Mobile Cardiac Telemetry Systems Market Trends/Analysis Report 2022-2030: Real-time Cardiac Monitoring and Self-care Management Boosting Demand - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Mobile Cardiac Telemetry Systems Market Size, Share & Trends Analysis Report by Application (Lead-based, Patch-based), by End use (Hospitals, Cardiac Centers), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mobile Cardiac Telemetry Systems Market Size, Share & Trends Analysis Report by Application (Lead-based, Patch-based), by End use (Hospitals, Cardiac Centers), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing prevalence of the cardiovascular disorder, need for effective arrhythmia management, and technological advancement in telemetry devices are driving the market.
  • Increasing demand for real-time cardiac monitoring and self-care management is boosting the demand for mobile cardiac telemetry devices.
  • The mobile cardiac telemetry devices read cardiac rhythm with the help of external devices consisting of metal sensors.

More Than Half of Physicians Have Been Asked By Patients for an Unapproved COVID-19 Treatment

Retrieved on: 
Wednesday, March 16, 2022

More than half (54%) of physicians surveyed reported that a patient has asked them for an unapproved COVID-19 treatment such as Ivermectin and Hydroxychloroquine.

Key Points: 
  • More than half (54%) of physicians surveyed reported that a patient has asked them for an unapproved COVID-19 treatment such as Ivermectin and Hydroxychloroquine.
  • Also, more than half (55%) of physicians reported that COVID-19 vaccine misinformation is increasingly becoming an issue when meeting with patients.
  • Other types of misinformation heard by physicians from patients include:
    More than half (51%) of physicians reported hearing from patients that they dont need a COVID-19 vaccine if theyve already had Covid.
  • Conspiracy theories about microchips in vaccines have made their way to the doctors office as 29% of physicians reported hearing this from patients.

Accord Healthcare Inc. Announces Launch of First-to-Market Additional Strengths of Hydroxychloroquine Sulfate Tablets, in the U.S.

Retrieved on: 
Wednesday, February 16, 2022

DURHAM, N.C., Feb. 16, 2022 /PRNewswire/ -- Accord Healthcare, having received final FDA approval, is pleased to announce the launch of additional strengths of Hydroxychloroquine Sulfate tablets in dosages of 100mg, 300mg and 400mg.

Key Points: 
  • DURHAM, N.C., Feb. 16, 2022 /PRNewswire/ -- Accord Healthcare, having received final FDA approval, is pleased to announce the launch of additional strengths of Hydroxychloroquine Sulfate tablets in dosages of 100mg, 300mg and 400mg.
  • Prior to Accord's offering of additional strengths, the only strength available was 200mg.
  • "This launch is the culmination of our team's ability to recognize that there was a serious need for additional strengths of Hydroxychloroquine," said Jeff Hampton, President, Accord Healthcare.
  • "The launch of our additional strengths of Hydroxychloroquine reinforces our commitment to empowering physicians and patients by providing them with the access they need to essential medicines."

Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022

Retrieved on: 
Friday, February 11, 2022

This data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from February 12-16.

Key Points: 
  • This data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from February 12-16.
  • These latest data demonstrate that Veklury was generally well tolerated among pediatric patients hospitalized with COVID-19 with a high proportion of participants showing clinical improvement and recovery.
  • Of the 53 pediatric patients enrolled in the study, no new safety signals were apparent for Veklury.
  • Please see below for more information on the approved use of Veklury and the EUA for pediatric patients.